<DOC>
	<DOCNO>NCT02771210</DOCNO>
	<brief_summary>The purpose study demonstrate efficacy , include effect inflammation magnetic resonance imaging ( MRI ) assessment , secukinumab Achilles tendon enthesitis 1 year primary focus Week 24 , patient active Psoriatic Arthritis axial Spondyloarthritis despite current previous non-steroidal anti-inflammatory drug ( NSAID ) and/or disease modify anti-rheumatic drug ( DMARD ) therapy .</brief_summary>
	<brief_title>Study Efficacy Safety Secukinumab Psoriatic Arthritis Axial Spondyloarthritis Patients With Active Enthesitis Including One Achilles Tendon Site</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Psoriatic</mesh_term>
	<mesh_term>Spondylarthritis</mesh_term>
	<mesh_term>Tendinopathy</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Key Patients Psoriatic arthritis : Diagnosis Psoriatic arthritis per Classification criterion Psoriatic Arthritis ( CASPAR criterion ) symptoms least 6 month active Psoriatic arthritis assess &gt; 1 tender joint 78 &gt; 1 swollen joint 76 Baseline ( dactylitis digit count one joint ) . Patients Axial Spondyloarthritis : Diagnosis Axial Spondyloarthritis per classification Assessment Spondyloarthritis International Society axial Spondyloarthritis ( ASAS ) criteria objective sign inflammation Screening ( magnetic resonance imaging ( MRI ) definite radiographic sacroilitis and/or abnormal CReactive Protein ) active disease assess total Bath ankylose spondylitis disease activity index ( BASDAI ) ≥ 4 ( 010 ) Baseline . Diagnosis Achilles tendon enthesitis accord swell tenderness insertional site Achilles tendon calcaneus . Onset heel pain ≥ 1 month 5 year Baseline . Heel enthesitis magnetic resonance imaging ( MRI ) positive accord investigator ` judgement . Patients Tumor necrosis factor ( TNF ) inhibitornaive . Key Chest Xray chest magnetic resonance imaging ( MRI ) evidence ongoing infectious malignant process . Previous exposure secukinumab biologic drug directly target Interleukin ( IL ) 17 Interleukin ( IL ) 17 receptor . Ongoing use psoriasis treatment / medication ( e.g . topical corticosteroid , ultraviolet ( UV ) therapy ) randomization . Patients previously treat Tumor necrosis factor ( TNF ) inhibitor ( investigational approve ) . Patients ever receive biologic immunomodulating agent ( investigational approve ) . Pregnant nursing ( lactate ) woman . History ongoing , chronic recurrent infectious disease evidence tuberculosis infection . Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Active psoriatic arthritis</keyword>
	<keyword>Axial spondyloarthritides</keyword>
	<keyword>Subcutaneous</keyword>
	<keyword>Secukinumab prefilled syringe</keyword>
	<keyword>Enthesitis</keyword>
	<keyword>Achilles tendon</keyword>
</DOC>